Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate if giving insulin that is administered in the nostrils (intranasal)
is safe and tolerable for people with multiple sclerosis (MS). It is also being done to
evaluate if intranasal insulin improves cognitive function in people with MS and to evaluate
how it might be working.